: EU regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm

The European Medicines Agency is reviewing data on the popular new class of drugs used for weight loss and Type 2 diabetes.

Previous post Key Words: Biden administration official advises student-loan borrowers to make payments during grace period: ‘It’s not a pause’
Next post The Ratings Game: Netflix has been getting a lot of love lately. Could that spell trouble ahead of earnings?